BioVent was founded on February 2006, in order to develop novel molecules for the treatment of human and avian influenza infections. BioVent technology is based on a research of the world renowned scientist Prof. Ruth Arnon. The research was published in the Journal of Biological Chemistry (Vol. 279 (2004), No. 46, pp. 48410–48419).
BioVent develops novel and patent protected DNA oligonucleotides (aptamers) designed to selectively and potently block the binding of influenza virus to target cells receptors and consequently to prevent the virus invasion into the host cells. The aptamers were designed to specifically interact with the Hemagglutinin (HA) glycoprotein located on the virus envelope.
Inhibition of various strains of influenza viral infection, including avian flu, has been clearly demonstrated in various in vitro and in vivo (mice) studies. Both prophylactic and therapeutic effects were shown in vivo.
For further information please contact Dr. Daniel Katz email@example.com